hrp0086wg5.7 | ESPE Diabetes Technology and Therapeutics Working Group | ESPE2016

The Interaction Between Human and Technology in the Treatment of Diabetes

Barnard Katharine

Background: Research has demonstrated that technologies to support diabetes self-management for people living with diabetes can have positive effects on medical and quality of life outcomes. It also shows that there may be an additional burden of wearing and using these technologies. Both diabetes and its treatment can have significant deleterious effect on quality of life, thus it is crucial that the interaction between the technology and the user offers maximum benefit with ...

hrp0094p2-160 | Diabetes and insulin | ESPE2021

HbA1C stability – is posting samples reliable?

Davey Nicola , Wright Katherine , Natarajan Anuja ,

For the safe delivery of Paediatric Diabetes services at DBTH during the COVID pandemic a postal HbA1c service with patients collecting capillary blood samples to send to the laboratory for analysis was proposed. The aim of this pilot study was to assess stability of HbA1c at ambient temperature in capillary whole blood samples collected into Sarstedt Microvette EDTA tubes. Samples were analysed on the day of collection on the TOSOH G11 analyser and then re-assayed daily for u...

hrp0095p1-465 | Fat, Metabolism and Obesity | ESPE2022

Use of liraglutide for treatment of childhood obesity: early experiences from a tier 3 paediatric obesity service

Hawton Katherine , Wenn Melanie , Hamilton-Shield Julian , Giri Dinesh

Background: Liraglutide is a glucagon-like peptide analogue which was approved for use in children and young people as an option for managing obesity in December 20201. It is to be used in tier 3 services alongside a reduced-calorie diet and increased physical activity in children more than 12 years if they have a BMI SDS age-equivalent more than 30kg/m2 for adults. We describe our initial experiences of using liraglutide in a tier 3 paed...

hrp0095p2-210 | Multisystem Endocrine Disorders | ESPE2022

Glucose dysregulation and Diabetes mellitus in ROHHAD syndrome - possibly centrally driven?

Hawton Katherine , Candler Toby , Hamilton-Shield Julian , Giri Dinesh

Background: Rapid-onset obesity with hypothalamic dysregulation, hypoventilation and autonomic dysregulation (ROHHAD) is a rare syndrome with a high risk of morbidity and mortality. Blood glucose dysregulation is not widely recognised as a feature of ROHHAD and the mechanism is not well understood. We describe glucose dysregulation in two children with ROHHAD syndrome.Case 1: The patient presented at 6 years with rapid w...

hrp0094p2-303 | Growth and syndromes (to include Turner syndrome) | ESPE2021

A literature review of the potency and selectivity of FGFR-selective tyrosine kinase inhibitors, such as infigratinib, in the potential treatment of achondroplasia

Dobscha Katherine , Wei Ge , Dambkowski Carl , Rogoff Daniela ,

Background: Germline mutations in fibroblast growth factor receptor (FGFR) genes 1–3 can cause skeletal dysplasias such as achondroplasia (ACH), which is caused primarily by a G380R substitution in FGFR3. Infigratinib (BGJ398), a potent and selective FGFR1–3 tyrosine kinase inhibitor (TKI), demonstrated preclinical efficacy at low doses in an ACH mouse model. The objective of this analysis is to evaluate dose dependency and toxicity...

hrp0097fc10.2 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) & Multisystem endocrine disorders | ESPE2023

Immune profile response to rituximab in ROHHAD syndrome

Hawton Katherine , Hamilton-Shield Julian , Hogan Andrew , Giri Dinesh

Background: Rapid-onset obesity with hypoventilation, hypothalamic dysfunction, autonomic dysregulation (ROHHAD) is a rare syndrome associated with high morbidity and mortality presenting with rapid onset of obesity in early childhood. An immune-inflammatory aetiology has been postulated; however, the immune profile is not well described.Case report: We report the case of a five-year-old female who presented in respirato...

hrp0097rfc13.1 | Pituitary, neuroendocrinology and puberty 2 | ESPE2023

Are Glucagon-like peptide-1 (GLP-1) receptor agonists a new treatment option for hypothalamic obesity in the paediatric population: Preliminary experience from a tertiary paediatric endocrine centre

Chatterjee Sumana , Hawton Katherine , Giri Dinesh , Crowne Elizabeth

Background: Hypothalamic obesity (HO), defined as abnormal weight gain due to physical hypothalamic destruction, for example due to suprasellar tumours, is characterised by significant hyperphagia, lack of satiety, and rapid weight gain in the first year of hypothalamic insult. HO is not usually responsive to caloric restriction or lifestyle modification, and no pharmacotherapies are specifically approved for treating HO. GLP-1 agonists, which suppress appetit...

hrp0089fc11.6 | Bone, Growth Plate & Mineral Metabolism 2 | ESPE2018

Management of Severe, Protracted Hypocalcaemia in Patients Undergoing Thymus Transplantation in a Tertiary Centre: A 10-Year Experience

Goff Nicole , Katugampola Harshini , Monti Elena , Taylor Katherine , Amin Rakesh , Hindmarsh Peter , Peters Catherine , Pratik Shah , Spoudeas Helen , Dattani Mehul , Allgrove Jeremy , Brain Caroline

Background: Thymus transplantation is undertaken for conditions associated with severe immunodeficiency. These comprise a number of genetic and syndromic associations including 22q deletion syndrome, CHARGE association, diabetic embryopathy, and other rarer conditions. These conditions may also be associated with hypoparathyroidism and patients are therefore at risk of severe hypocalcaemia. There are no published guidelines for calcium replacement in these patients during the ...

hrp0095rfc6.6 | Sex Development and Gonads | ESPE2022

Differently Normal: Making sense of Adolescent Perspectives of Early Childhood Experiences associated with Congenital Adrenal Hyperplasia (CAH)

Siese Thomas , Alderson Julie , Hickingbotham Hannah , Hawton Katherine , Skae Mars , Crowne Elizabeth

Background: There is limited reporting of the impact of genital difference on early childhood experience, although the young person’s viewpoint should be at the core of patient centred clinical decision making. The experience of girls living with Congenital Adrenal Hyperplasia (CAH) may differ according to context, being influenced by interactions within the family, with specialist teams as well as prevailing social values. Clearly there is a need to inv...

hrp0086rfc2.5 | Bone & Mineral Metabolism | ESPE2016

Growth Patterns and Fractures in Boys with Duchenne Muscular Dystrophy: Insights from Over 800 Boys in the UK North Star Cohort

Joseph Shuko , Bushby Katherine , Guglieri Michela , Horrocks Iain , Ahmed S Faisal , Wong S C

Background: There is little information on growth and fractures in boys with Duchenne Muscular Dystrophy (DMD).Objective & hypotheses: To determine the extent of growth & skeletal morbidity in a contemporary cohort of DMD in the UK.Method: Clinical details of 832 boys with DMD in the North Star database (2006–2015) from 23 centres were analysed following categorisation into five age groups: A:<5 years (n, ...